Altimmune Appoints New CMO, Director; Reports Officer Compensation
Ticker: ALT · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1326190
| Field | Detail |
|---|---|
| Company | Altimmune, Inc. (ALT) |
| Form Type | 8-K |
| Filed Date | Jun 26, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, officer-appointment
TL;DR
Altimmune beefs up leadership with a new CMO and board member.
AI Summary
Altimmune, Inc. announced on June 25, 2024, the appointment of Dr. Vipin Garg as Chief Medical Officer and the election of Dr. Amy Comstock, MD, to its Board of Directors. The company also reported on its compensatory arrangements for certain officers. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
Changes in key leadership roles and board composition can signal strategic shifts or new directions for the company's drug development and business operations.
Risk Assessment
Risk Level: medium — Changes in executive and board positions can introduce uncertainty regarding future strategy and execution, impacting investor confidence.
Key Players & Entities
- Altimmune, Inc. (company) — Registrant
- Vipin Garg (person) — Appointed Chief Medical Officer
- Amy Comstock, MD (person) — Elected to Board of Directors
- June 25, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Altimmune, Inc.?
Dr. Vipin Garg has been appointed as the new Chief Medical Officer of Altimmune, Inc.
Who has been elected to Altimmune, Inc.'s Board of Directors?
Dr. Amy Comstock, MD, has been elected to Altimmune, Inc.'s Board of Directors.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 25, 2024.
What type of SEC filing is this document?
This document is a Current Report on Form 8-K.
What are the main items of information disclosed in this 8-K filing?
The filing discloses the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD Disclosure, and Financial Statements and Exhibits.
Filing Stats: 639 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2024-06-26 07:33:35
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Mar
Filing Documents
- alt-20240625x8k.htm (8-K) — 43KB
- alt-20240625xex99d1.htm (EX-99.1) — 15KB
- alt-20240625xex99d1002.jpg (GRAPHIC) — 7KB
- 0001326190-24-000022.txt ( ) — 189KB
- alt-20240625.xsd (EX-101.SCH) — 3KB
- alt-20240625_lab.xml (EX-101.LAB) — 16KB
- alt-20240625_pre.xml (EX-101.PRE) — 10KB
- alt-20240625x8k_htm.xml (XML) — 5KB
01 Regulation
Item 7.01 Regulation On June 26, 2024, the Company issued a press release, the entire text of which is attached as Exhibit 99.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits No. Description 99.1 Press Release of Altimmune, Inc. dated June 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALTIMMUNE, INC. By: /s/ Vipin K. Garg Name: Vipin K. Garg Title: President, Chief Executive Officer Dated: June 26, 2024